KOLEK, V., I. GRYGÁRKOVÁ, J. CHALUPA, L. KOUBKOVÁ, T. JANÁSKOVÁ, J. ROUBEC, P. POPELKOVÁ, T. BÁRTEK, D. SIXTOVÁ, E. PAVLÍKOVÁ, T. VLÁSEK, F. CHALOUPKA and Jana SKŘIČKOVÁ. Oral vinorelbine in combination with carboplatin in adjuvant chemotherapy of non-small cell lung cancer (NSCLC): A prospective multicentre study of feasibility, tolerability and short time survival. In 13th Central European Lung Cancer Conference. 2012. ISSN 0169-5002. doi:10.1016/j.lungcan.2012.05.064.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Oral vinorelbine in combination with carboplatin in adjuvant chemotherapy of non-small cell lung cancer (NSCLC): A prospective multicentre study of feasibility, tolerability and short time survival
Authors KOLEK, V., I. GRYGÁRKOVÁ, J. CHALUPA, L. KOUBKOVÁ, T. JANÁSKOVÁ, J. ROUBEC, P. POPELKOVÁ, T. BÁRTEK, D. SIXTOVÁ, E. PAVLÍKOVÁ, T. VLÁSEK, F. CHALOUPKA and Jana SKŘIČKOVÁ.
Edition 13th Central European Lung Cancer Conference, 2012.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.392
Organization unit Faculty of Medicine
ISSN 0169-5002
Doi http://dx.doi.org/10.1016/j.lungcan.2012.05.064
UT WoS 000305842300065
Keywords in English lung cancer; erlotinib
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 17. 8. 2012 14:14.
Abstract
Adjuvant cisplatinum-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA of non small-cell lung cancer (NSCLC) after radical resection. Results in stage IB were not conclusive. Vinorelbine is a preferable associated drug in this indication and a randomized study proved the comparable effectiveness and tolerability of vinorelbine given both orally or intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine gives better comfort to patients. The tolerance of adjutant chemotherapy and implementation of planned dose intensity remains a substantial problem, which most likely reflects the difficulty associated with CDDP-based chemotherapy. NCIC CTG BR.10, IALT and ANITA trials reported treatment-related deaths, accounting for 0.8–1.7%. In ANITA trial, median of planned dose was 56.3% in NVB and 76.1% in CDDP. Only 50% of patients finished all of 4 cycles planned. New studies targeting more tolerable regimens are needed. CDDP-based treatment is preferred, but several studies showed similar effectiveness and better tolerance of the combination of carboplatin (AUC5) and paclitaxel, pemetrexed or vinorelbine. Only few data exist about vinorelbine given orally in adjuvant chemotherapy (ACT).
Type Name Uploaded/Created by Uploaded/Created Rights
Skrickovlung_cancer_002.pdf   File version Petr, M. 17. 8. 2012

Rights

Right to read
 
Right to upload
 
Right to administer:
  • a concrete person prof. MUDr. Jana Skřičková, CSc., učo 1808
  • a concrete person Mgr. Michal Petr, učo 65024
Attributes
 
Print
Ask the author for author copy Displayed: 24. 7. 2021 13:34